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Background: Leishmania amazonensis infection results in diverse clinical manifestations: cutaneous, mucocutaneous
or visceral leishmaniasis. The arsenal of drugs available for treating Leishmania infections is limited. Therefore, new,
effective, and less toxic leishmaniasis treatments are still needed. We verified cell death in amastigote forms of
Leishmania amazonensis induced by the sesquiterpene lactone parthenolide.
Results: The tested compound was able to concentration-dependently affect axenic and intracellular amastigotes,
with IC50 values of 1.3 μM and 2.9 μM, respectively after 72 h incubation. No genotoxic effects were observed in a
micronucleus test in mice. Parthenolide induced morphological and ultrastructural changes in axenic amastigotes,
including a loss of membrane integrity, swelling of the mitochondrion, cytoplasmic vacuoles, and intense exocytic
activity in the region of the flagellar pocket. These results led us to investigate the occurrence of autophagic vacuoles
with monodansylcadaverine and the integrity of the plasma membrane and mitochondrial membrane potential using
flow cytometry. In all of the tests, parthenolide had positive results.
Conclusions: Our results indicate that the antileishmanial action of parthenolide is associated with autophagic vacuole
appearance, a reduction of fluidity, a loss of membrane integrity, and mitochondrial dysfunction. Considering the limited
repertoire of existing antileishmanial compounds, the products derived from medicinal plants has been one the greatest
advances to help develop new chemotherapeutic approaches.
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Leishmaniasis is associated with high morbidity but low
mortality. It is a poverty-related disease and has become
a serious impediment to socioeconomic development.
The true burden of this illness remains unclear because
the notification of the disease is compulsory in only 32
of the 88 affected countries, and most of the affected
people live in remote areas. Additionally, the disfiguring
scars caused by Leishmania keep patients hidden. An es-
timated 1.5 million new cases of cutaneous leishmaniasis
and 500,000 cases of visceral leishmaniasis occur annually,
with approximately 12 million people currently infected [1].
Moreover, cases of Leishmania and human immunodefi-
ciency virus co-infection are becoming more frequent [2,3].
Leishmania (Leishmania) amazonensis infection results
in diverse clinical manifestations, ranging from cutaneous* Correspondence: cvnakamura@uem.br
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unless otherwise stated.to mucocutaneous or visceral involvement [4]. This is
attributable to the genetic diversity of L. amazonensis
strains, and this divergence extends to variations of
chromosome size [5].
The arsenal of drugs available for treating Leishmania
infections is limited. The basic treatment consists of
administering pentavalent antimonial compounds [6].
However, the choice of medication depends on the species
involved and type of clinical manifestation [7]. The useful-
ness of antileishmanial drugs has been limited by their
toxicity, and treatment failure is often attributable to drug
resistance [8]. To solve this problem, developing less toxic
drugs and discovering cellular and molecular markers in
parasites to identify the phenotype of chemoresistance
against leishmanicidal drugs are necessary [8,9]. These
problems led to the development of additional antileish-
manial drugs. Some drug-delivery systems, plants, and
synthetic compounds are being developed as effective
treatments for the disease [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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parthenolide, a sesquiterpene lactone purified from Tana-
cetum parthenium, against promastigotes and intracellular
amastigotes (inside J774G8 macrophages) of L. amazonen-
sis [10]. Moreover, significant alterations in promastigote
forms were demonstrated by light microscopy and scan-
ning and transmission electron microscopy [11].
We evaluated the activity of parthenolide against L.
amazonensis axenic amastigotes and demonstrated a
possible mechanism of action of this compound in this
life stage of the parasite.
Results
Antileishmanial assays
The addition of 4.0 μM parthenolide to the culture of
axenic amastigotes induced growth arrest and partial cell
lysis after 48 h (i.e., growth inhibition up to 90%). When
the cells were treated with 2.0 μM parthenolide, the per-
centage of growth inhibition was approximately 70%.
Parthenolide had an IC50 of 1.3 μM and IC90 of 3.3 μM
after 72 h incubation (Figure 1A).Figure 1 Effects of parthenolide (A) and amphotericin B (B) on the gr
different concentrations of the drugs, parasites were counted, and the perc
The data indicate the average of the two independent experiments perform
compared statistically at p < 0.05. Bars that are not indicated with letters inA concentration of 1.0 or 0.5 μM of the reference drug
amphotericin B inhibited more than 93% of L. amazonensis
amastigote cell growth. This drug had an IC50 and IC90 of
0.22 μM and 0.45 μM, respectively, after culturing for 72 h
(Figure 1B).
Parthenolide also inhibited the growth of intracellular
amastigotes in mouse resident peritoneal macrophages
after 24 h incubation. Treatment with 4.0, 3.2, 2.4, and
1.6 μM parthenolide reduced the proliferation of parasites
into macrophages (survival index) by 82.5, 59.4, 37.3, and
6.1%, respectively, compared with the control. The
survival index indicated that parthenolide inhibited the
intracellular viability and multiplication of Leishmania in
infected murine macrophages and showed 50% inhibition
of cell survival at a concentration of 2.9 μM (Figure 2).
Previous studies showed that when J774G8 murine mac-
rophages were treated with parthenolide, the 50% cytotoxic
concentration (CC50) was 56.4 μM [10]. By comparing the
toxicity for J774G8 macrophages and activity against intra-
cellular amastigotes, obtaining the selectivity index ratio is
possible (CC50 for J774G8 cells/IC50 for protozoa). In theowth of L. amazonensis axenic amastigotes. After treatment with
entage of parasite growth inhibition was determined daily for 120 h.
ed twice. Statistical analysis: the data of each incubation period were
common are statistically different.
Figure 2 Effect of parthenolide on amastigotes of L. amazonensis in mouse resident peritoneal macrophages. Peritoneal macrophage
cells were infected with promastigote forms, and then intracellular amastigotes were treated with different concentrations of parthenolide. After
24 h treatment, the survival index was calculated by multiplying the percentage of macrophages with internalized parasites and mean number of
internalized parasites per macrophage. The results shown are from one representative experiment of two independent experiments performed in
duplicate. The data were compared statistically at p < 0.05. Bars that are not indicated with letters in common are statistically different.
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ing a selectivity index ratio of 19.4 (i.e., the compound is
19.4-times more selective against parasites than host cells).
Mutagenicity evaluation
The results of the in vivo bone marrow micronucleus test
in rats are shown in Table 1. Parthenolide did not induce
genotoxic effects at a concentration of 3.75 mg/kg body
weight, with no significant increase in the frequency of
MNPCE (10.0 ± 1.6) compared with the vehicle control
group (7.0 ± 1.8). In contrast, a significant increase in the
frequency of MNPCE was observed in the positive control
group (cyclophosphamide; 27.0 ± 4.0). In the present
study, no clinical signs of toxicity were observed in treated
animals. However, further studies should be performed
with higher concentrations of parthenolide to exclude the
possibility of genotoxicity.
Scanning and transmission electron microscopy
To determine the morphological and ultrastructural
changes in L. amazonensis axenic amastigotes induced by
parthenolide, the cells were treated with the IC50 (1.3 μM)Table 1 Micronucleated polychromatic erythrocyte (MNPCE)
score in 2,000 reticulocytes from bone marrow of mice
Treatment MNPCE (mean ± SD)
Vehicle 7.0 ± 1.8
Cyclophosphamide 27.0 ± 4.0b
Parthenolide 10.0 ± 1.6a
Findings after 24 h oral treatment with vehicle (negative control),
cyclophosphamide (positive control), and parthenolide.
aNo significant difference compared with negative control and significant
difference compared with positive control (p < 0.05).
bSignificant difference compared with negative control (p < 0.05).of the compound. Untreated controls showed no morpho-
logical (Figure 3A) or ultrastructural (Figure 3D) differ-
ences. Similarly, cells incubated with 0.05% DMSO (i.e.,
the same concentration used in the final solutions of
parthenolide) remained unaltered (data not shown). When
treated with parthenolide, changes in form were visualized
by scanning electron microscopy (Figure 3B and C).
Transmission electron microscopy showed a loss of mem-
brane integrity associated with amphotericin B exposure at
the IC50 concentration (Figure 3E). Parthenolide caused
intense swelling of the mitochondrion (Figure 3F) and
cytoplasmic blebbing (Figure 3G). Finally, the ultrastruc-
tural analysis showed that amastigotes treated with parthe-
nolide formed multiple cytoplasmic vacuoles (Figure 3H),
and intense exocytic activity was observed in the region of
the flagellar pocket, appearing as concentric membranes
within the pocket (Figure 3I).Labeling of autophagic vacuoles with
monodansylcadaverine
We studied the incorporation of monodancylcadaverine
(MDC) in cells in which autophagy was stimulated by
parthenolide. Axenic amastigotes treated with the IC50
(Figure 4B) or IC90 (Figure 4C) of parthenolide showed
an increase in the number of vesicles, indicating that the
compound induced the formation of MDC-labeled vacu-
oles in the cytoplasm. MDC-positive cells were visual-
ized in treated cells but not in control cells (Figure 4A)
or amphotericin-treated cells (data not shown). These
results show that parthenolide treatment, unlike ampho-
tericin B, led to the formation of autophagic vacuoles in
L. amazonensis amastigotes.
Figure 3 Scanning (A-C) and transmission (D-I) electron microscopy of axenic amastigotes of L. amazonensis treated with parthenolide.
Amastigotes were incubated for 72 h in the absence (A and D) or presence (B, C, F-I) of the IC50 (1.3 μM) of parthenolide. For transmission
electron microscopy, the treatment of amastigotes was also accomplished using the IC50 of amphotericin B as a reference drug that acts on the
cytoplasmic membrane (E). The arrows indicate plasma membrane blebs or loss of membrane integrity, and the asterisks indicate vesicles located
in the cytoplasm or flagellar pocket. n, nucleus; f, flagellum; fp, flagellar pocket; m, mitochondrion; k, kinetoplast. Scale bars = 1 μm.
Figure 4 Monodansylcadaverine (MDC)-labeled vesicles in axenic amastigotes of L. amazonensis induced by parthenolide treatment.
Amastigotes were incubated for 72 h in Schneider medium (control cells) (A) or in the presence of the IC50 (B) or IC90 (C) of parthenolide. The
data are representative of at least three independent experiments. Scale bars = 5 μm.
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Live L. amazonensis cells were incubated with propidium
iodide and rhodamine 123, and fluorescence was measured
by flow cytometry. The gated percentage of propidium
iodide-stained amastigotes after treatment with amphoteri-
cin B (positive control) was 71.4%, much higher than un-
treated parasites (negative control) that presented 6.0%
(Figure 5A). When the cells were treated with 20 and
40 μM parthenolide, the percentages of labeled amastigotes
were 34.2% and 56.2%, respectively (Figure 5B), possibly
indicating a considerable increase in plasma membrane
permeability. To prove that Leishmania cells functionally
respond to the pharmacological alteration of ΔΨm, amasti-
gotes were treated with the protonophore carbonyl cyanide
m-chlorophenylhydrazone (CCCP), which has been shown
to interfere with mitochondrial membrane potential in
various cell types [12]. The results showed that 82.5% of
the amastigotes without treatment (negative control) pre-
sented a maximal increase in fluorescence, and with
200 μM CCCP, 46.7% showed fluorescence, indicating a
loss of ΔΨm (Figure 5C). We next observed ΔΨm reduc-
tions of 68.4% and 56.1% when the amastigotes were
treated with 20 and 40 μM parthenolide, respectively,Figure 5 Flow cytometry analysis of propidium iodide- (A, B) and rho
(A) Untreated cells: negative control (C-) and amphotericin B as positive co
20 or Pt 40). (C) Untreated cells: negative control and carbonyl cyanide m-
with 20 or 40 μM parthenolide (Pt 20 or Pt 40). The data are representativesuggesting that this compound interferes with the mito-
chondrial membrane potential leading to alteration of ATP
generation and in consequence cell damage takes place.
EPR spectra of spin-labeled Leishmania
The experimental and best-fit EPR spectra of spin-label 5-
DSA structured in the plasma membrane of Leishmania
are shown in Figure 6. These EPR spectra are typical for
cellular membranes that contain an appreciable amount
of integral proteins. Treatment with parthenolide in-
creased two EPR parameters, the outer hyperfine splitting,
2A//, and rotational correlation time, τC, indicating a sig-
nificant reduction of membrane lipid dynamics. 2A//is a
practice parameter measured directly in EPR spectra that
has been widely used to monitor membrane fluidity, al-
though in principle it is a static parameter associated with
the orientation distribution of the spin labels in the mem-
brane. The theoretical EPR spectrum of spin-label 5-DSA
in the plasma membrane of Leishmania was best fitted
using a model of two spectral components. This indicates
that the membrane has two populations of spin labels of
distinct mobility. The EPR spectra of spin labels in lipid
bilayers are well known to contain proteins sometimesdamine 123- (C, D) labeled axenic amastigotes of L. amazonensis.
ntrol (C+). (B) Amastigotes treated with 20 or 40 μM parthenolide (Pt
chlorophenylhydrazone as a positive control. (D) Amastigotes treated
of at least two independent experiments.
Figure 6 Experimental EPR spectra (black line) and theoretical fits (red line) of spin-label 5-DSA in Leishmania membrane. The experiment
was conducted at 26°C for samples untreated and treated with parthenolide at the indicated concentrations. EPR spectra were simulated with the
NLLS fitting program, and the values of the parameter rotational correlation time, τC, obtained from the fit for each spectrum are indicated on a
nanosecond scale. The EPR parameter 2A//is the separation in magnetic-field units between the first and last resonance lines of the spectrum. The
vertical lines indicate the 2A//for the control samples, and the smaller vertical lines illustrate the increase in 2A//for the sample treated with 9 × 10
9
molecules/cell. The measured 2A//values and τC values indicate that the presence of parthenolide significantly reduced lipid fluidity. The estimated
experimental errors for the 2A//and τC parameters are 0.5 G and 1.0 ns, respectively.
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stricted component is associated with boundary lipids
where the spin labels surround the hydrophobic regions
of proteins, whereas the more mobile component arises
from the spin labels located in the bulk bilayer phase,
away from the protein [13]. The fitting program pro-
vides the τc and population of each component. Thus,
the mean of the rotational correlation time was calcu-
lated as τc = N1*τc1 + N2*τc2, in which N1 and N2 are the
fractions of the population in components 1 and 2,
respectively, and τc1 and τc2 are the corresponding rota-
tional time correlations.Discussion
For many years, parasites of the genus Leishmania have dis-
played extraordinary plasticity to face modifications in their
environment [14]. The expansion of risk factors related to
environmental changes and man-made transformations are
making leishmaniasis a growing public health concern in
many countries worldwide [15]. Leishmaniasis urgently
needs novel drugs with improved features, and many com-
pounds primarily derived from plants are promising leads
for the development of novel chemotherapeutics [16].
The development of axenic cultures of amastigotes of
Leishmania species yielded new opportunities to investigate
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the mammalian stage of the parasite [17]. Assays that use
intracellular amastigote cell cultures are relevant because
this life cycle stage of the parasite is important to its patho-
genicity, and data obtained exclusively from promastigote
cell lines are insufficient [16]. Therefore, in the present
study, we determined the leishmanicidal activity of parthe-
nolide, which is naturally occurring, in both axenic and
intracellular amastigotes.
To discover better leishmanicidal compounds, the isola-
tion and purification of the active ingredients of medicinal
plants are gaining attention [18]. Many new natural prod-
uct groups, such as terpenes, have exhibited antiprotozoal
potential and attracted renewed interest with surprising
efficacy and selectivity [19].
Parthenolide is a lipophilic hydrocarbon compound
formed by units of isoprene. The accumulation of lipo-
philic compounds in the cytoplasmic membrane and
membrane constituents of microorganisms has consider-
able effects on the loss of cellular integrity and inhibition
of respiratory cellular activity in mitochondria [20]. This
interaction with cell membranes eventually leads to cell
death. In our research, parthenolide had antileishmanial
effects against axenic and intracellular amastigotes of L.
amazonensis presenting IC50 of 1.3 after 72 h growth and
2.9 μM after 24 h growth, respectively. The differences in
IC50 values can be explained because the experiments with
axenic amastigotes are directed against the relevant stage
of the parasite whereas the use of intracellular amastigotes
will give essential information on the capacity of the drugs
to target intracellular organisms. The role played by the
macrophages on drug-mediated toxicity may be import-
ant. Their presence may limit the availability of the com-
pounds under evaluation [21,22].
The toxicity for J774G8 macrophages and the activity
against intracellular amastigotes were compared by using
the selectivity index ratio (CC50 for J774G8 cells/IC50 for
protozoa) [10]. The parthenolide was more selective
against the intracellular amastigotes than the mamma-
lian cells, with a selectivity index ratio of 19.4. It is gen-
erally considered that biological efficacy is not due to
in vitro cytotoxicity when this index is ≥ 10 [23,24].
The low toxicity against mammalian cells is an import-
ant criterion in the search for active compounds with
antiprotozoal activity. For this purpose, the genotoxicity
of parthenolide in a mouse model was determined using
a micronucleus test and cyclophosphamide as the posi-
tive control because it is a known genotoxin [25]. Micro-
nuclei are masses of cytoplasmic chromatin that appear
outside the main nucleus as a result of chromosomal
damage or damage to the mitotic apparatus in the eryth-
roblasts of the test species, and they can be used as an
indicator of the effects of agents that cause DNA dam-
age [26]. In mice, micronuclei in mature erythrocytes inperipheral blood live approximately 1 month, providing
a measure of average chromosomal damage [27]. Our re-
sults showed no differences in the frequency of MNPCE
compared with the negative control, demonstrating no
toxic effects on bone marrow at the dose tested
(3.75 mg/kg body weight).
Electron microscopic studies revealed extensive cyto-
plasmic vacuolization, leading to the examination of the
possibility that parthenolide induces autophagic cell death.
Autophagy cell death is a process that is thought to occur
in all eukaryotes and is characterized by an accumulation
of autophagic vacuoles. This mechanism occurs for energy
production for survival when cells recycle their cyto-
plasmic contents during periods of environmental stress
or certain stages of development. A double-membrane
vesicle called the autophagosome forms in the cytosol,
engulfing organelles and bulk cytoplasm. Subsequently,
these vesicles fuse with lysosomes, where their contents
are degraded and recycled [28]. One of the most fre-
quently used methods to examine autophagy is staining
with acidotropic dyes [29], and MDC is considered an
autofluorescent compound and specific marker for au-
tophagic vacuoles [30]. MDC staining is only obtained
when the compartments into which it loads are acidic.
Neutralization of these compartments leads to a swift loss
of MDC staining or lack of MDC uptake [31]. Therefore,
we suggest that the vacuoles that were observed under a
transmission electron microscope are autophagosomes.
Another study used MDC as a marker to analyze the mo-
lecular level of the machinery involved in the autophagic
process [32] and was also used to demonstrate that anti-
microbial peptides induce autophagic cell death in L.
donovani [33].
Amphotericin B was used as a positive control in some
of our experiments because this polyene antibiotic forms
aqueous and nonaqueous pores in membranes, which is
the basis of leishmanicidal action [34]. Using transmission
electron microscopy, we could see the loss of membrane
integrity induced by this antimicrobial agent. Similarly, al-
terations in the cytoplasmic membrane, including mem-
brane blebbing and disruption, could be visualized in
axenic amastigotes treated with parthenolide. Studies have
shown that a flow cytometric membrane potential assay
can be used as a reliable tool for studying the interactions
between amphotericin B and the Leishmania membrane
[35]. Alterations in membrane permeability are detected
by propidium iodide nucleic acid stain that selectively
passes through plasma membranes and bind to DNA,
emitting high fluorescence when excited by an argon ion
laser [36]. Since its introduction, the propidium iodide
flow cytometric assay has also been widely used as a quan-
titative measure of cell apoptosis. During apoptosis, DNA
fragmentation occurs, with a subsequent loss of cellular
DNA content [37].
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the cellular and mitochondrial membrane structures of
different pathogenic agents, modifying their permeability
and integrity [20]. Ultrastructural findings also revealed
mitochondrial damage induced by parthenolide. We used
flow cytometry analysis to determine whether the com-
pound interferes with the mitochondrial membrane
potential of the amastigotes. The flow cytometry results
showed that transmembrane potential decreased, reflected
by a reduction of rhodamine 123 fluorescence. Rhodamine
123 is a fluorescent cationic stain for mitochondria in
living cells and is subsequently washed out of the cells
once the mitochondrion’s membrane potential is lost [38].
The present results indicated an increase in proton per-
meability through the internal mitochondrial membrane,
inhibition of electron transport, or decrease in mitochon-
drial substrate transport/oxidation, which would impair
proton pumping by mitochondrial complexes and reduce
adenosine triphosphate synthesis, resulting in parasite cell
death [39]. CCCP was used as positive control because it is
an uncoupler of oxidative phosphorylation and reduces
mitochondrial membrane potential by directly attacking the
proton gradient across the inner mitochondrial membrane
[12,40]. Amastigotes treated with parthenolide presented
severe plasma membrane and mitochondrial damage, sug-
gesting an autophagic process [39].
Treatment with parthenolide induced shedding of the
membranes into the flagellar pocket, appearing as concen-
tric membranes and suggesting intense exocytic activity
because this site is where endocytosis and exocytosis
occur in trypanosomatids. Treatment of promastigote
forms of L. amazonensis with edelfosine for 1 day [41] and
parthenolide for 3 days [10] also led to the appearance of
a large number of vesicles inside the flagellar pocket, sug-
gesting a process of exacerbated protein production by
cells as they attempt to survive.
Other studies indicated that the plasma membrane of
human promyelocytic leukemic HL-60 cells appears to be
one of the targets of parthenolide because its integrity is
lost very early during cell death, reflected by atypical
apoptosis and primary necrosis (i.e., lysis of the mem-
brane) [42].
The lipid spin probe 5-DSA was incorporated into the
plasmatic membrane of Leishmania in the usual way, and
the EPR spectra obtained were typical for cell membranes.
Interestingly, the spectra of the Leishmania membrane
were very similar to those for the same spin label in
erythrocyte membranes [43]. The erythrocyte membrane
of spin-labeled lipids has been well characterized by EPR
spectroscopy and is considered to have certain rigidity,
particularly because of its high content of protein and
cholesterol. The presence of sesquiterpene parthenolide
significantly increased the rigidity of the membrane of
Leishmania when applied to the cell suspension at a ratioof 3 × 109 parthenolide molecules/cell. Parthenolide also
showed dose-dependent anti-Leishmania activity against
the amastigote form. The IC50 was 1.3 μM parthenolide/
ml for a cell concentration of 1 × 106 cell/ml. Therefore,
the effect of parthenolide against the amastigote forms of
Leishmania was observed at a ratio of 7.8 × 108 partheno-
lide molecules/cell. The greatest change in membrane flu-
idity was observed at a concentration 3.8-fold higher than
for growth inhibition. Membrane stiffness, assessed by
EPR spectroscopy of the spin label, has been associated
with lipid peroxidation [44,45]. A detailed study of the
interaction between parthenolide and membranes and
their role as a pro-oxidant in simpler systems is necessary
to determine whether the membrane rigidity observed
here was attributable to lipid peroxidation.
Conclusions
Our results indicated that the antileishmanial action of
parthenolide is associated with autophagic vacuole appear-
ance, membrane stiffness, the loss of membrane integrity,
and mitochondrial dysfunction. These results indicate that
parthenolide induced amastigote cell death by autophagy,
but other mechanisms of cell death cannot be dismissed,
such as apoptosis and necrosis. Considering the limited
repertoire of existing antileishmanial compounds, con-
tinuously developing new leishmanicidal compounds is es-
sential. In the ongoing search for the best antileishmanial
compounds, products derived from plants are gaining
ground. The isolation and purification of the active com-
ponents of medicinal plants has been one the greatest
advances. Additionally, delineation of the biochemical
mechanisms involved in mediating effect of these com-




Parthenolide (minimum 90%) was purchased from Sigma-
Aldrich (Steinheim, Germany). Amphotericin B (Cristália,
Produtos Químicos Farmacêuticos Ltda, Itapira, SP, Brazil)
was used as a positive control. In all of the tests, 0.05%
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA)
was used to dissolve the highest dose of the compounds
and had no effect on the parasites’ proliferation or
morphology.
Axenic amastigotes
Promastigotes of the Leishmania species differentiate to
amastigotes with the combination of low pH and high
temperature [46]. The WHOM/BR/75/Josefa strain of
Leishmania amazonensis, isolated by C.A. Cuba-Cuba
(University of Brasília, Brasília, Distrito Federal, Brazil)
from a human case of diffuse cutaneous leishmaniasis,
was used in the present study. Axenic amastigote cultures
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gotes from the stationary phase in 25 cm2 tissue culture
flasks by progressive temperature increase and pH
decrease [47]. The cultures were maintained at 32°C in
Schneider’s insect medium (Sigma, St. Louis, MO, USA),
pH 4.6, with 20% fetal bovine serum through weekly serial
sub-culturing for further studies.
Antiproliferative effect
For the parasite growth inhibition assays, L. amazonensis
axenic amastigotes were harvested during the exponential
phase of growth, and 106 cells were added to each well of
a 24-well plate and treated with different concentrations
of parthenolide and amphotericin B. Medium alone and
0.05% DMSO were used as negative controls. For each
treatment, the parasites were observed and counted daily
using a Neubauer chamber with an optical microscope.
Each experiment was performed in duplicate and twice on
different occasions. The antiproliferative effect (percentage
of growth inhibition) was evaluated with 5 day treatment,
and the data are expressed as the mean ± standard error
of the mean (Microsoft Excel). The corresponding 50%
and 90% inhibitory concentrations (IC50 and IC90) were
determined from the concentration-response curves
(Excel software). Data were compared via one-way analysis
of variance (ANOVA) followed by Tukey’s multiple range
test for statistically significant differences at p < 0.05.
Activity of parthenolide in infection of murine
macrophages
The effect of parthenolide on L. amazonensis-infected
mouse peritoneal macrophages was evaluated. The experi-
mental protocol was approved by the Animal Ethics Com-
mittee of the Universidade Estadual de Maringá (no. 013/
2010). BALB/c mice resident peritoneal cells were har-
vested in phosphate-buffered saline (PBS; 0.01 M, pH 7.2)
and centrifuged, and the sediment was resuspended in
RPMI 1640 medium supplemented with 10% fetal bovine
serum. Cells (1 × 105) were seeded on 13-mm coverslips in
24-well plates and incubated at 37°C in a 5% CO2 atmos-
phere. After 15 h, macrophages were infected with
promastigotes at a 10:1 parasite:cell ratio and incubated
again for 6 h. The remaining noninternalized parasites
were removed. The infected host cells were treated with
parthenolide at concentrations of 4.0, 3.2, 2.4, and 1.6 μM.
After 24 h, the coverslips were washed with PBS, fixed in
methanol, stained with Giemsa, mounted in Entellan
(Merck), and examined under an optical microscope. The
rate of cell infection and number of amastigotes per cell
were evaluated by counting 200 random cells in duplicate
cultures in at least two independent experiments. The sur-
vival index was calculated by multiplying the percentage
of infected macrophages and mean number of internalized
parasites per macrophage. Data were compared via one-way analysis of variance (ANOVA) followed by Tukey’s
multiple range test for statistically significant differences
at p < 0.05.
Genotoxicity study
To assess the toxicity of parthenolide in mice, a micronu-
cleus test was conducted in groups of five male and five fe-
male Swiss albino mice (Mus musculus) that weighed
approximately 42 g. The animals were obtained from the
Central Animal House of the Universidade Estadual de
Maringá, Paraná, Brazil. They were housed in plastic cages
at 22 ± 1°C and 55 ± 10% humidity, with a 12 h/12 h light/
dark cycle and free access to water and food (Nuvilab Cr1).
The study was conducted according to experimental stan-
dards approved by the Animal Ethics Committee of the
Universidade Estadual de Maringá (protocol no. 013/2010).
The animals received 3.75 mg parthenolide/kg body
weight suspended in 10% DMSO by oral gavage. The
negative control was a vehicle group, and the positive con-
trol was a group that received 40 mg cyclophosphamide/
kg body weight. The mice were examined regularly for
mortality and clinical signs of toxicity until sacrifice by
carbon dioxide asphyxiation, which occurred 24 h after
treatment. Both femurs were dissected, and bone marrow
was flushed with fetal calf serum. After centrifugation for
5 min at 2,000 × g, 10 μl of the sediment was smeared on
glass slides and air-dried. The smears were fixed with ab-
solute methanol for 5 min and stained with May-
Grunwald-Giemsa to detect micronucleated polychro-
matic erythrocytes (MNPCE). The number of micronu-
cleated cells was counted in 2,000 reticulocytes per animal
using an Olympus BH-2 microscope at 1,000× magnifica-
tion [26]. The statistical analyses were made with a one-
way analysis of variance (ANOVA) followed by Dunnet
test. Differences were considered significant at p value of
less than 0.05.
Scanning and transmission electron microscopy
After treatment with the IC50 (72 h) of parthenolide,
axenic amastigotes were washed in PBS and fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer at 4ºC.
For scanning electron microscopy, amastigotes were
placed on a specimen support with a poly-L-lysine-coated
coverslip and washed in cacodylate buffer. The cells were
dehydrated in an increasing ethanol gradient, critical-
point-dried in CO2, sputter-coated with gold, and ob-
served in a Shimadzu SS-550 SEM scanning electron
microscope.
For transmission electron microscopy, amastigote forms
were treated with the IC50 of parthenolide and the IC50 of
amphotericin B and fixed as described above. The cells
were postfixed in a solution that contained 1% osmium
tetroxide, 0.8% potassium ferrocyanide, and 10 mM cal-
cium chloride in 0.1 M cacodylate buffer, dehydrated in an
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Ultrathin sections were stained with uranyl acetate and
lead citrate, and the images were examined in a Zeiss 900
transmission electron microscope.
Fluorescence of monodansylcadaverine during cell death
Axenic amastigotes were treated with IC50 and IC90 equiv-
alents of parthenolide. After 72 h, the cells were washed
and resuspended in PBS. To verify the induction of au-
tophagy by parthenolide, the cells were incubated with
0.05 mM monodansylcadaverine (MDC) at 37°C for
10 min. After incubation, the cells were washed three times
with PBS to remove excess MDC, immediately analyzed by
fluorescence microscopy at an excitation wavelength of
360–380 nm and emission wavelength of 525 nm, and
photographed using a charge-coupled-device camera. This
study was qualitative.
Flow cytometry
The antileishmanial activity of parthenolide (20 and
40 μM) on the integrity of the plasma membrane and
mitochondrial membrane potential of axenic amastigotes
(5 × 106 cells/ml) was determined after 3 h treatment.
Amphotericin B (5.0 μM) and carbonyl cyanide m-chloro-
phenylhydrazone (200 μM) were used as positive controls.
Untreated amastigotes were used as a negative control.
Each flow-cytometric technique was evaluated by repeat-
ing each experiment three times to verify reproducibility.
The integrity of the plasma membrane was assessed
using L. amazonensis amastigotes at an average density of
5 × 106 cells suspended in 500 μl PBS and stained with
50 μl propidium iodide (2 μg/ml) for 5 min at room
temperature.
To measure mitochondrial membrane potential (ΔΨm),
1 ml of saline that contained 1 × 106 of treated amastigotes
was mixed with 1 μl rhodamine 123 (5 mg/mL) for
15 min at 37°C. The cells were washed, resuspended in
PBS, and incubated at the same temperature for 30 min.
A total of 10,000 events were analyzed per sample
using a FACSCalibur cytometer, and numeric data were
processed with Cellquest software (both from Becton
Dickinson). Propidium iodide and rhodamine 123 are
excited with a 480 nm argon ion laser, and fluorescence
emission occurs at 560–580 nm and 515–530 nm,
respectively.
Electron paramagnetic resonance spectroscopy
Spin-label 5-doxyl stearic acid (5-DSA), with a nitroxide
radical moiety (doxyl) in the fifth carbon atom of the acyl
chain, was purchased from Sigma (St. Louis, MO, USA).
A small aliquot (3 μl) of stock solution of the spin label in
ethanol (2 mg/ml) was transferred to a glass tube. After
the solvent evaporated, approximately 2.4 × 108 cells of
Leishmania suspended in 40 μl PBS was added to the filmof the spin label with gentle agitation. In a second tube,
6 μl of a stock solution of parthenolide in chloroform
(201 mM) was added. After evaporation of the solvent, the
first spin-labeled cell suspension was placed on the
parthenolide film and gently agitated. The cells were then
introduced into a 1 mm inner diameter capillary column
for electron paramagnetic resonance (EPR) measure-
ments, which was sealed by flame. Samples were also pre-
pared that contained double and triple the concentrations
of parthenolide used in the first sample (using 12 and
18 μl of the solution of parthenolide in chloroform,
respectively).
Electron paramagnetic resonance spectroscopy was per-
formed with a Bruker ESP 300 spectrometer (Rheinstetten,
Germany) equipped with an ER 4102 ST resonator. The in-
strument settings were the following: microwave power,
10 mW; modulation frequency, 100 KHz; modulation
amplitude, 1.0 G. Electron paramagnetic resonance spectra
simulations were performed using the NLLS program de-
veloped by Budil and coworkers [48]. In the spectral calcu-
lations, the NLLS program includes the magnetic g- and
A-tensors and rotational diffusion tensor, R, which are
expressed in a system of Cartesian axes fixed in the spin-
labeled molecule. To reduce the number of parameters in
the fittings and simplify the simulation, the average rota-
tional diffusion rate, Rbar, was calculated by the fitting pro-
gram using the relationship Rbar = (Rper
2 •Rpar)
1/3, in which
Rper is the perpendicular component of the rotational diffu-
sion, and Rpar is the parallel component of the rotational
diffusion. Rbar was converted to the parameter rotational
correlation time, τc, following the relationship τc = 1/6 Rbar.
Similar to previous studies [49,50], the magnetic parame-
ters were determined based on a global analysis of the
overall spectra obtained in this work, and all of the EPR
spectra were simulated using the same predetermined pa-
rameters. In this work, the spectra were simulated with a
model of two spectral components.Competing interests
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